MA29310B1 - Composes inhibiteurs de raf et procedes - Google Patents

Composes inhibiteurs de raf et procedes

Info

Publication number
MA29310B1
MA29310B1 MA30151A MA30151A MA29310B1 MA 29310 B1 MA29310 B1 MA 29310B1 MA 30151 A MA30151 A MA 30151A MA 30151 A MA30151 A MA 30151A MA 29310 B1 MA29310 B1 MA 29310B1
Authority
MA
Morocco
Prior art keywords
methods
inhibiting compounds
raf
raf inhibiting
pyrazolyl compounds
Prior art date
Application number
MA30151A
Other languages
English (en)
Inventor
Ellen Laird
Joseph P Lyssikatos
Mike Welch
Jonas Grina
Josh Hansen
Brad Newhouse
Alan Olivero
George Topolav
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of MA29310B1 publication Critical patent/MA29310B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS PYRAZOLYLE REPRÉSENTÉS PAR LA FORMULE IA QUI CONVIENNENT POUR INHIBER LA KINASE RAF ET POUR TRAITER DES TROUBLES INDUITS PAR CELLE-CI. CETTE INVENTION CONCERNE AUSSI DES PROCÉDÉS D'UTILISATION DES COMPOSÉS PYRAZOLYLE DE FAÇON À DIAGNOSTIQUER, PRÉVENIR OU TRAITER IN VITRO, IN SITU ET IN VIVO CES TROUBLES DANS DES CELLULES MAMMALIENNES OU DES ÉTATS PATHOLOGIQUES ASSOCIÉS.
MA30151A 2005-02-04 2007-08-17 Composes inhibiteurs de raf et procedes MA29310B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65005005P 2005-02-04 2005-02-04

Publications (1)

Publication Number Publication Date
MA29310B1 true MA29310B1 (fr) 2008-03-03

Family

ID=36571626

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30151A MA29310B1 (fr) 2005-02-04 2007-08-17 Composes inhibiteurs de raf et procedes

Country Status (18)

Country Link
US (2) US7491829B2 (fr)
EP (1) EP1846391A2 (fr)
JP (1) JP2008530011A (fr)
KR (1) KR20070107104A (fr)
CN (1) CN101282960A (fr)
AR (1) AR053014A1 (fr)
AU (1) AU2006210626A1 (fr)
BR (1) BRPI0607346A2 (fr)
CA (1) CA2596973A1 (fr)
CR (1) CR9365A (fr)
IL (1) IL185024A0 (fr)
MA (1) MA29310B1 (fr)
MX (1) MX2007009405A (fr)
NO (1) NO20074473L (fr)
RU (1) RU2007133111A (fr)
TW (1) TW200639163A (fr)
WO (1) WO2006084015A2 (fr)
ZA (1) ZA200707289B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003456A (es) 2006-10-02 2009-04-14 Irm Llc Compuestos y composiciones como inhibidores de proteina cinasa.
BRPI0718310A2 (pt) 2006-10-17 2013-11-19 Stiefel Laboratories Metabólitos de talarozol
WO2009039387A1 (fr) * 2007-09-20 2009-03-26 Wyeth Pyrazolo[5,1-c]-[1,2,4]-triazines et leurs procédés de préparation et d'utilisation
WO2009111277A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de raf
WO2009108827A1 (fr) * 2008-02-29 2009-09-03 Wyeth Pyrazolo[1,5-a]pyrimidines tricycliques condensées, procédés pour les préparer et leurs utilisations
EP2265574A1 (fr) 2008-02-29 2010-12-29 Array Biopharma, Inc. Dérivés de n-(6-aminopyridin-3-yl)-3-(sulfonamido) benzamide comme inhibiteurs de b-raf pour le traitement du cancer
CN102015707A (zh) * 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
WO2009111260A1 (fr) * 2008-02-29 2009-09-11 Wyeth Pyrazolo[1,5-a]pyrimidines substituées par phénylsulfonamide, leurs procédés de préparation et leurs utilisations
EP2265610B1 (fr) * 2008-02-29 2012-12-12 Array Biopharma, Inc. Inhibiteurs de raf de pyrazole[3,4-b]pyridine
JP2009286773A (ja) * 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
EP2300013B2 (fr) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Dérivés phosphorés servant d'inhibiteurs de kinase
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
EP2440058A4 (fr) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc Composés hétérocycliques fondus et leurs utilisations
JP2013503190A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
CA2772316A1 (fr) 2009-08-28 2011-03-03 Array Biopharma Inc. Composes 1h-pyrazolo[3,4-b]pyridines pour l'inhibition des raf kinases
EP2470538A1 (fr) 2009-08-28 2012-07-04 Array Biopharma, Inc. Composés inhibiteurs de raf et leurs procédés d'utilisation
JP2013503189A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
SG178899A1 (en) 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
WO2011051478A1 (fr) * 2009-10-30 2011-05-05 Domain Therapeutics Nouveaux dérivés d'oximes et leur utilisation comme modulateurs allostériques de récepteurs métabotropiques du glutamate
EP2937345B1 (fr) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (fr) 2010-08-25 2012-02-29 Bayer CropScience AG Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides
UA112534C2 (uk) 2010-10-27 2016-09-26 Байєр Інтеллектуал Проперті Гмбх Похідні гетероарилпіперидину, проміжні сполуки, композиція для боротьби із шкідливими фітопатогенними грибами та спосіб її виготовлення
WO2012094451A1 (fr) 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Nouvelles urées pour le traitement et la prévention du cancer
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
KR101848116B1 (ko) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체
WO2012145503A1 (fr) 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
EP2704572B1 (fr) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
EP2739358B1 (fr) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de mek
WO2013043715A1 (fr) 2011-09-19 2013-03-28 Genentech, Inc. Polythérapies comportant des antagonistes de c-met et de b-raf
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
DK2921495T3 (en) 2011-12-27 2018-07-16 Bayer Ip Gmbh HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES
RS55196B1 (sr) 2011-12-31 2017-01-31 Beigene Ltd Fuzionisana triciklična jedinjenja kao inhibitori raf kinaze
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JP6335169B2 (ja) 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
EP3046557A1 (fr) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
WO2015058140A1 (fr) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs polycycliques de kinase cycline-dépendante 7 (cdk7)
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
EP3154589A1 (fr) 2014-06-13 2017-04-19 Genentech, Inc. Méthodes de traitement et de prévention de la résistance du cancer aux médicaments
WO2015196072A2 (fr) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
MX388181B (es) 2014-07-22 2025-03-19 Cb Therapeutics Inc Anticuerpos anti-pd-1.
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10351559B2 (en) 2015-04-15 2019-07-16 Beigene, Ltd. Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
PL3377107T3 (pl) 2015-11-19 2020-12-14 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego
WO2018007885A1 (fr) 2016-07-05 2018-01-11 Beigene, Ltd. Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
WO2018102725A1 (fr) 2016-12-01 2018-06-07 Arvinas, Inc. Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des œstrogènes
EP3558994A4 (fr) * 2016-12-23 2021-05-12 Arvinas Operations, Inc. Composés et methodes pour la dégradation ciblée de polypeptides de fibrosarcome rapidement accéléré
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018137681A1 (fr) 2017-01-25 2018-08-02 Beigene, Ltd. Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, préparation et utilisations associées
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
EP3732285A1 (fr) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020140098A1 (fr) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase dépendante des cyclines 7 et leurs utilisations
ES3061133T3 (en) 2019-08-26 2026-03-31 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021120890A1 (fr) 2019-12-20 2021-06-24 Novartis Ag Dérivés pyrazolyle utiles en tant qu'agents anticancéreux
EP4204418A1 (fr) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
AU2021342287A1 (en) 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
MX2023005078A (es) * 2020-10-30 2023-05-16 Novartis Ag Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4442680A4 (fr) * 2021-11-30 2026-05-06 Abbisko Therapeutics Co Ltd Dérivé de pyrazole, son procédé de préparation et son utilisation en médecine
WO2024022186A1 (fr) * 2022-07-29 2024-02-01 四川科伦博泰生物医药股份有限公司 Composé méthylpyrazole, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
EP4584258A1 (fr) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1245283A (en) 1968-10-04 1971-09-08 Labaz Pyrazole derivatives
JP2753659B2 (ja) 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
JPH05125079A (ja) 1991-11-05 1993-05-21 Otsuka Pharmaceut Factory Inc ピラゾロ［１，５−ａピリミジン誘導体
KR100315837B1 (ko) 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
AU707530B2 (en) 1995-09-28 1999-07-15 Otsuka Pharmaceutical Factory, Inc. Analgesic composition
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
AR037061A1 (es) 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2000153671A (ja) 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 感熱記録材料
AU4556800A (en) 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
IL145757A (en) 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
WO2001056557A2 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de erk
WO2001056993A2 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions de pyrazole utiles en tant qu'inhibiteurs d'erk
DE60103136T2 (de) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
WO2002024680A1 (fr) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
ES2294047T3 (es) 2000-12-28 2008-04-01 Ono Pharmaceutical Co., Ltd. Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
DE60223339T2 (de) 2001-01-22 2008-08-28 Sankyo Co., Ltd. Durch bicyclische aminogruppen substituierte verbindungen
EP1370557B1 (fr) * 2001-03-09 2005-11-16 Pfizer Products Inc. Composes de benzimidazole anti-inflammatoires
JP4310109B2 (ja) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
HRP20030961B1 (en) * 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
EP1423380B1 (fr) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinase derives du pyrazole et leurs utilisations
JP4357295B2 (ja) 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040010027A1 (en) * 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
ES2295441T3 (es) * 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
EP1456180B1 (fr) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles et leur utilisation medicale
ATE365740T1 (de) 2002-05-10 2007-07-15 Smithkline Beecham Corp Substituierte pyrazolopyrimidine
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
AU2003256297A1 (en) * 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US6967254B2 (en) 2002-09-09 2005-11-22 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1543001B1 (fr) 2002-09-17 2007-08-15 Eli Lilly And Company Derives de pyrazolopyridine en tant qu'inhibiteurs de tgf-beta pour le traitement des maladies de cancer
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
AU2003268155A1 (en) 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
EP1567527A1 (fr) 2002-11-27 2005-08-31 Eli Lilly And Company Derives pyrazolo condenses
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
CN101282960A (zh) 2008-10-08
AR053014A1 (es) 2007-04-18
AU2006210626A1 (en) 2006-08-10
ZA200707289B (en) 2009-09-30
BRPI0607346A2 (pt) 2009-09-01
TW200639163A (en) 2006-11-16
IL185024A0 (en) 2007-12-03
NO20074473L (no) 2007-10-31
WO2006084015A2 (fr) 2006-08-10
KR20070107104A (ko) 2007-11-06
RU2007133111A (ru) 2009-03-10
EP1846391A2 (fr) 2007-10-24
CA2596973A1 (fr) 2006-08-10
MX2007009405A (es) 2007-09-25
WO2006084015A3 (fr) 2006-11-23
US20060189627A1 (en) 2006-08-24
CR9365A (es) 2008-01-15
US7491829B2 (en) 2009-02-17
US20090176809A1 (en) 2009-07-09
JP2008530011A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
MA32271B1 (fr) Composes inhibiteurs de kinases raf et procedes d'utilisation
TW200639163A (en) RAF inhibitor compounds and methods
MX2021012122A (es) Inhibidores de la proteina tirosina fosfatasa.
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
WO2006125101A3 (fr) Composes inhibiteurs raf et procedes d'utilisation de ceux-ci
CR20210189A (es) Inhibidores de la proteina tirosina fosfatasa
TNSN07071A1 (fr) Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
WO2007146824A3 (fr) Quinolines et méthodes d'utilisation
MY146644A (en) Cyclohexylamin isoquinolone derivatives
WO2007027855A3 (fr) Composes inhibiteurs de la raf kinase et procedes d'utilisation de ceux-ci
UA111933C2 (uk) Піролопіридини як інгібітори кінази
MA42145B1 (fr) Triazoles agonistes du récepteur apj
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
MA32134B1 (fr) Composés hétérocycliques
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
TN2009000551A1 (fr) Nouveaux composes chimiques
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2008028141A3 (fr) Composés inhibiteurs de la kinase raf et procédés d'utilisation de ceux-ci
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.